急性冠脉综合症患者中阿托伐他汀与辛伐他汀对hs―CRPMMP2CD40L水平影响研究.docVIP

急性冠脉综合症患者中阿托伐他汀与辛伐他汀对hs―CRPMMP2CD40L水平影响研究 　　【摘 要】目的：观察在急性冠脉综合症（ACS）患者中阿托伐他汀与辛伐他汀对高敏C反应蛋白（hs-CRP）、基质金属蛋白酶2（MMP2）、白细胞分化抗原40配体（CD40L）水平的影响，探讨他汀类药物在ACS患者中的抗炎作用。 　　方法：选取ACS组患者96例，正常对照组34例。其中ACS组随机分A组：辛伐他汀20mg/d，B组：阿托伐他汀20mg/d；分别测定治疗前后患者外周血hs-CRP、MMP2、CD40L、总胆固醇（TC）、甘油三酯（TG）、低密度脂蛋白胆固醇（LDL-C）的水平，进行临床疗效观察。 　　结果：阿托伐他汀治疗组与辛伐他汀治疗组之间治疗后的血脂结果未见明显差异（P0.05），但他汀类药物治疗4周后hs-CRP、MMP2、CD40L水平明显下降（P值？）；阿托伐他汀组较辛伐他汀组及对照组hs-CRP、MMP2、CD40L水平下降更加明显（P值？）。 　　结论：他汀类药物具有独立于降脂作用以外的抗炎作用，减缓动脉粥样硬化进程和管腔狭窄、稳定冠脉斑块，从而阻止或延缓ACS的发生发展。此外阿托伐他汀比辛伐他汀在抗炎方面更有优势。 　　【关键词】hs-CRP；MMP2；CD40L；阿托伐他汀 　　The effect of atorvastatin and simvastatin upon hs-CRP，MMP2，CD40L level in patients with acute coronary syndrome 　　Abstrac：Objective：To observe the effects of the atorvastatin and simvastatin on high sensitive C-reactive protein（hs-CRP），matrix metalloproteinase 2（MMP2），CD40 ligand（CD40L）levels in acute coronary syndrome（ACS）patients，so as to probe into the anti-inflammatory influence of statins in ACS patients. 　　Methods：Select 96 patients with ACS and normal control group of 34 patients.The ACS group are randomly divided into Group A：Simvastatin 20mg / d，Group B：atorvastatin 20mg / d.To assay the level of hs-CRP，MMP2，CD40L，total cholesterol（TC），triglyceride（TG），low density lipoprotein cholesterol（LDL-C）before and after treatment.Along with clinical efficacy observation. 　　Results：There is no significant differences in blood lipid results between atorvastatin and simvastatin treatment group（P 0.05）.However，the levels of hs-CRP，MMP2 and CD40L decreased obviously with statin therapy after 4 weeks.The levels of hs-CRP，MMP2 and CD40L declined more apparently in atorvastatin statin group rather than those in simvastatin group. 　　Conclusions：Besides lipid-lowering effects，the statins have independent effect of anti-inflammatory，slow the process of atherosclerosis and stenosis，make coronary plaque stable，so as to prevent or delay the occurrence and development of ACS.And found that atorvastatin have an advantage over